A drug that harnesses the immune system to attack cancer cells has proved successful in preventing a rare and aggressive form ...

Cancer is a broad term used to describe the uncontrollable proliferation of mutated cells deleterious to the body. Any tissue in the body can become mutated and drive tumor progression. Unfortunately, ...

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body’s ...

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage III melanoma remained alive, according to new ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage III melanoma remained alive, according to new ...

A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy. Real-world data from a retrospective study demonstrates the ...

Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients ...

Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved outcomes post-surgery and radiation.